A Phase 4 interventional study of Benzoyl peroxide with clindamycin and Benzoyl peroxide with clindamycin and doxycycline in Acne, sponsored by Stiefel, a GSK Company. Completed at 2 sites in United States. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2017-05-25.
Sponsored by Stiefel, a GSK Company (part of GlaxoSmithKline) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 33 studies testing Benzoyl Peroxide in Acne Vulgaris — none open to participants now, 1 under way, none of them phase 3. Benzoyl Peroxide · Acne Vulgaris.
Among the 33 studies testing Benzoyl Peroxide in Acne Vulgaris, this one is the 26th largest by enrollment, is one of 2 that started in 2007, is one of 16 in phase 4, and was the 9th registered.
791 studies on the registry are indexed under Acne Vulgaris; 93 are open to participants now.
Browse Acne Vulgaris studies →None of the 33 studies testing Benzoyl Peroxide in Acne Vulgaris is open now. The open studies under Acne Vulgaris, anywhere →
Benzoyl Peroxide: first FDA approval 1984 (BENZAMYCIN). What it is approved for, and how studies give it, is on its page →
Of the 46 Acne Vulgaris studies recruiting now, 16 (35%) set no upper age limit and 29 (63%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.
This study: 16 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
33 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 2 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 33 is below the median of 70 across 673 interventional studies indexed under Acne Vulgaris.
Median enrollment 90 across the 33 interventional studies. Of the 28 that completed or were terminated, 24 (86%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 33 have an industry lead sponsor. The 10 most frequent:
This study is registered under Stiefel, a GSK Company, one of the names counted as GlaxoSmithKline. Under that name alone:
Stiefel, a GSK Company is the lead sponsor of 56 studies on the registry; none are open to participants now.
42 studies in Acne Vulgaris by GlaxoSmithKline: none open now, none under way, none of them phase 3. Of 42 finished, 24 (57%) have results posted.
Among the 42 studies in Acne Vulgaris by GlaxoSmithKline, this one is the 33rd largest by enrollment, is one of 2 that started in 2007, is one of 16 in phase 4, and was the 8th registered.
GlaxoSmithKline’s Acne Vulgaris studies by the year they started, since 2004.
None of the studies under way reaches primary completion within a year.
Among the 33 studies testing Benzoyl Peroxide in Acne Vulgaris, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 42 in Acne Vulgaris:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To compare the efficacy and safety of Benzoyl peroxide used in combination with clindamycin vs. Benzoyl peroxide used in combination with clindamycin and doxycycline in the treatment of moderate acne
To compare the efficacy and safety of Benzoyl peroxide used in combination with clindamycin vs. Benzoyl peroxide used in combination with clindamycin and doxycycline once daily in the treatment of moderate acne
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Benzoyl peroxide (BPO) wash with clindamycin foam
Drug: Benzoyl peroxide with clindamycin
Benzoyl peroxide (BPO) wash with clindamycin foam and doxycycline capsules
Drug: Benzoyl peroxide with clindamycin and doxycycline
Drug pages: Benzoyl Peroxide · Clindamycin
Benzoyl peroxide wash - Clindamycin foam
Also known as: Acne
Drug pages: Benzoyl Peroxide · Clindamycin · Doxycycline
Benzoyl peroxide wash - Clindamycin foam - Doxycycline capsules
Also known as: Acne
Percent Change in Inflammatory Acne Lesions From Baseline to Week 16
Percent change from baseline to week 16 in inflammatory acne lesions (pustules/papules)(chest and back)
Time frame: Baseline, Week 16
Percent (%) Change in Non-inflammatory Acne Lesions From Baseline to Week 16.
Percent change in Non-inflammatory acne lesions (whiteheads and blackheads)(chest and back) from baseline to week 16.
Time frame: Baseline, Week 16
Percent Change in Total Acne Lesion Counts From Baseline to Week 16
Percent change from baseline to week 16 in total acne lesions (inflammatory + non-inflammatory)
Time frame: Baseline, Week 16
Change in Investigator Global Assessment (IGA)
Change in Investigator Global Assessment (IGA) Average values chest and back. IGA scale: 0 - Clear 0.5 - Clear/almost clear 1. Almost Clear 1.5- Almost Clear/Mild 2. Mild 2.5- Mild/Moderate 3. Moderate 3.5- Moderate/Severe
Time frame: Baseline, Weeks 4, 8,12, and 16
Percent (%) Change in Inflammatory Lesion Counts (Chest and Back) From Baseline to Week 12
Percent change in inflammatory lesion counts (chest and back)from Baseline to Week 12
Time frame: Baseline, Week 12
Percent Change in Non-inflammatory Lesions (Chest and Back) From Baseline to Week 12
Percent change in non-inflammatory lesions (chest and back) from baseline to Week 12
Time frame: Baseline, Week 12
Percent Change in Total Lesions (Chest and Back) From Baseline to Week 12
Percent change in total lesions (chest and back) from baseline to Week 12
Time frame: Week 12
Percentage of Particpants With IGA Score at Week 16
Investigator Global Assessment (IGA) at Week 16 based on the Investigator Global Assessment IGA: 0 - Clear 0.5 - Clear/almost clear 1. Almost Clear 1.5- Almost Clear/Mild 2. Mild 2.5- Mild/Moderate 3. Moderate 3.5- Moderate/Severe
Time frame: Baseline, Week 16
Recruitment period: First Subject Enrolled May 2008, Last Subject completed August 28, 2008. Types of location: Dermatology Research Center
| Milestone | Benzoyl Peroxide Wash -Clindamycin Foam | Benzoyl Peroxide Wash -Clindamycin Foam -Doxycycline Capsules |
|---|---|---|
| Started | 16 | 17 |
| Completed | 10 | 12 |
| Not completed | 6 | 5 |
| Withdrew: Lost to follow-up | 3 | 2 |
| Withdrew: Withdrawal by subject | 2 | 2 |
| Withdrew: Not stated | 1 | 1 |
Percent change from baseline to week 16 in inflammatory acne lesions (pustules/papules)(chest and back)
| Percent change | Benzoyl Peroxide Wash -Clindamycin Foam | Benzoyl Peroxide Wash -Clindamycin Foam -Doxycycline Capsules |
|---|---|---|
| Percent Change in Inflammatory Acne Lesions From Baseline to Week 16 | -52.70 ± 26.83 | -48.84 ± 40.37 |
Percent change in Non-inflammatory acne lesions (whiteheads and blackheads)(chest and back) from baseline to week 16.
| Percent Change | Benzoyl Peroxide Wash -Clindamycin Foam | Benzoyl Peroxide Wash -Clindamycin Foam -Doxycycline Capsules |
|---|---|---|
| Percent (%) Change in Non-inflammatory Acne Lesions From Baseline to Week 16. | -25.27 ± 45.64 | -44.69 ± 43.72 |
Percent change from baseline to week 16 in total acne lesions (inflammatory + non-inflammatory)
| Percent Change | Benzoyl Peroxide Wash -Clindamycin Foam | Benzoyl Peroxide Wash -Clindamycin Foam -Doxycycline Capsules |
|---|---|---|
| Percent Change in Total Acne Lesion Counts From Baseline to Week 16 | -38.49 ± 33.06 | -46.11 ± 39.74 |
Percent change in inflammatory lesion counts (chest and back)from Baseline to Week 12
| Percent Change | Benzoyl Peroxide Wash -Clindamycin Foam | Benzoyl Peroxide Wash -Clindamycin Foam -Doxycycline Capsules |
|---|---|---|
| Percent (%) Change in Inflammatory Lesion Counts (Chest and Back) From Baseline to Week 12 | -49.04 ± 31.63 | -45.44 ± 46.09 |
Percent change in non-inflammatory lesions (chest and back) from baseline to Week 12
| Percent change | Benzoyl Peroxide Wash -Clindamycin Foam | Benzoyl Peroxide Wash -Clindamycin Foam -Doxycycline Capsules |
|---|---|---|
| Percent Change in Non-inflammatory Lesions (Chest and Back) From Baseline to Week 12 | -38.43 ± 39.75 | -38.52 ± 39.03 |
Percent change in total lesions (chest and back) from baseline to Week 12
| Percent change | Benzoyl Peroxide Wash -Clindamycin Foam | Benzoyl Peroxide Wash -Clindamycin Foam -Doxycycline Capsules |
|---|---|---|
| Percent Change in Total Lesions (Chest and Back) From Baseline to Week 12 | -44.16 ± 29.41 | -41.74 ± 38.56 |
Change in Investigator Global Assessment (IGA) Average values chest and back. IGA scale: 0 - Clear 0.5 - Clear/almost clear 1. Almost Clear 1.5- Almost Clear/Mild 2. Mild 2.5- Mild/Moderate 3. Moderate 3.5- Moderate/Severe
| Units on a scale | Benzoyl Peroxide Wash -Clindamycin Foam | Benzoyl Peroxide Wash -Clindamycin Foam -Doxycycline Capsules |
|---|---|---|
| Change from Baseline to Week 4 | -0.42 ± 0.57 | -0.61 ± 0.59 |
| Change from Baseline to Week 8 | -0.55 ± 0.88 | -0.85 ± 0.72 |
| Change from Baseline to Week 12 | -1 ± 1.07 | -1.09 ± 0.8 |
| Change from Baseline to Week 16 | -0.9 ± 0.94 | -1.25 ± 0.97 |
Investigator Global Assessment (IGA) at Week 16 based on the Investigator Global Assessment IGA: 0 - Clear 0.5 - Clear/almost clear 1. Almost Clear 1.5- Almost Clear/Mild 2. Mild 2.5- Mild/Moderate 3. Moderate 3.5- Moderate/Severe
| Percent of participants | Benzoyl Peroxide Wash -Clindamycin Foam | Benzoyl Peroxide Wash -Clindamycin Foam -Doxycycline Capsules |
|---|---|---|
| % Clear skin | 0 | 8.3 |
| % Clear or Almost Clear | 0 | 8.3 |
| % Almost Clear | 30 | 25 |
| % Almost clear/ mild | 10 | 8.3 |
| % Mild | 10 | 25 |
| % Mild/ Moderate | 20 | 8.3 |
| % Moderate | 30 | 16.7 |
Collected over 16 weeks. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Benzoyl Peroxide Wash -Clindamycin Foam | — | 0/13 (0%) | 4/13 (30.8%) |
| Benzoyl Peroxide Wash -Clindamycin Foam -Doxycycline Capsules | — | 0/14 (0%) | 4/14 (28.6%) |
| Event | Benzoyl Peroxide Wash -Clindamycin Foam | Benzoyl Peroxide Wash -Clindamycin Foam -Doxycycline Capsules |
|---|---|---|
| Cold/ Cold symptomsInfections and infestations | 2/13 | 1/14 |
| Stomach fluInfections and infestations | 1/13 | 0/14 |
| CoughInfections and infestations | 1/13 | 0/14 |
| HeadacheNervous system disorders | 0/13 | 1/14 |
| FeverInfections and infestations | 0/13 | 1/14 |
| Nausea/ vomitingInfections and infestations | 0/13 | 1/14 |
| DizzinessEar and labyrinth disorders | 0/13 | 1/14 |
| Age, Continuous(years) | Benzoyl Peroxide Wash -Clindamycin Foam | Benzoyl Peroxide Wash -Clindamycin Foam -Doxycycline Capsules | Total |
|---|---|---|---|
| Mean | 23.9 ± 8.5 | 21.9 ± 6.9 | 22.9 ± 7.7 |
| Sex: Female, Male(Participants) | Benzoyl Peroxide Wash -Clindamycin Foam | Benzoyl Peroxide Wash -Clindamycin Foam -Doxycycline Capsules | Total |
|---|---|---|---|
| Female | 7 | 9 | 16 |
| Male | 9 | 8 | 17 |
| Race/Ethnicity, Customized(Participants) | Benzoyl Peroxide Wash -Clindamycin Foam | Benzoyl Peroxide Wash -Clindamycin Foam -Doxycycline Capsules | Total |
|---|---|---|---|
| White | 10 | 12 | 22 |
| Asian | 3 | 0 | 3 |
| Hispanic | 2 | 3 | 5 |
| Black or African American | 1 | 2 | 3 |
The record gives a start of Aug 2007, a primary completion of Aug 2008 and a completion of Aug 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2010, 2 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Benzoyl Peroxide · Clindamycin · Doxycycline